跳轉至內容
Merck
全部照片(1)

Key Documents

View All Documentation

C0246

Sigma-Aldrich

Cabergoline

≥98% (HPLC)

同義詞:

1-Ethyl-3-(3′-dimethylaminopropyl)-3-(6′-allylergoline-8′β-carbonyl)urea, 1-[(6-Allylergoline-8β-yl)carbonyl]-1-[3-(dimethylamino)-propyl]-3-ethylurea, Cabaser, Dostinex, FCE-21336

登入查看組織和合約定價
全部照片(1)

About This Item

經驗公式（希爾表示法）:
C26H37N5O2
CAS號碼:
81409-90-7
分子量：:
451.60
MDL號碼:
MFCD00867887
分類程式碼代碼:
12352200
PubChem物質ID:
329774771
NACRES:
NA.77

品質等級

100

化驗

≥98% (HPLC)

形狀

powder

光學活性

[α]/D −63 to −74°, c = 0.5 in dichloromethane

溶解度

DMSO: ≥10 mg/mL

起源

Johnson & Johnson

儲存溫度

2-8°C

SMILES 字串

CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1

InChI

1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1

InChI 密鑰

KORNTPPJEAJQIU-KJXAQDMKSA-N

基因資訊

human ... DRD2(1813)

尋找類似的產品？ 前往 產品比較指南

生化／生理作用

Cabergoline, a lysergic acid amide derivative, is a potent dopamine D2 receptor agonist. It also acts on dopamine receptors in lactophilic hypothalamus cells to suppress prolactin production in the pituitary gland. It has been used for monotherapy of Parkinson′s disease in the early phase; combination therapy, together with levodopa and a decarboxylase inhibitor such as carbidopa, in progressive-phase Parkinson′s disease and adjunctive therapy of prolactin-producing pituitary gland tumors (microprolactinomas).

特點和優勢

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

象形圖

Exclamation mark
GHS07

訊號詞

Warning

危險聲明

H302,H362

危險分類

Acute Tox. 4 Oral - Lact.

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Samuel Santos-Ribeiro et al.
Journal of assisted reproduction and genetics, 32(7), 1063-1068 (2015-05-20)
We report on the results of the whole-genome analysis performed in a patient who developed severe ovarian hyperstimulation syndrome (OHSS) following gonadotropin-releasing hormone (GnRH) agonist triggering in a "freeze-all" protocol. A 30-year-old patient with polycystic ovary syndrome who developed severe
Annamaria Colao et al.
Nature clinical practice. Endocrinology & metabolism, 2(4), 200-210 (2006-08-26)
Prolactinoma is the most frequent pituitary tumor histotype. Men generally have macroadenomas whereas women generally have microadenomas. The major objectives of treating prolactinomas are to suppress excessive hormone secretion and its clinical consequences, to remove the tumor mass while preserving
M C Porter et al.
International journal of clinical practice, 56(6), 468-474 (2002-08-09)
Dopamine agonists have diverse chemical and physical properties that can directly stimulate the dopamine receptors, unlike levodopa which undergoes presynaptic breakdown to dopamine before dopaminergic effects in Parkinson's disease (PD). Cabergoline, a dopamine agonist effective given once daily, is being
Renata S Auriemma et al.
European journal of endocrinology, 169(3), 359-366 (2013-07-05)
Cabergoline (CAB) has been found to be associated with increased risk of cardiac valve regurgitation in Parkinson's disease, whereas several retrospective analyses failed to detect a similar relation in hyperprolactinemic patients. The current study aimed at investigating cardiac valve disease
Monique P Curran et al.
Drugs, 64(18), 2125-2141 (2004-09-03)
Cabergoline is a synthetic ergoline dopamine agonist with a high affinity for dopamine D2 receptors and a long elimination half-life. This agent provides continuous dopaminergic stimulation with once-daily administration. Adjuvant oral cabergoline is usually well tolerated and effective in controlling
查看所有相關論文

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務